• Why Deals Die

Why complex deals stall, and where they actually die

No-decision is rising, win rates are flat, and forecasts are unreliable. Deals die in the gap between discovery and the business case, long before the final pitch. This is the diagnosis.

The industry built an artificial gap between discovery and case building. Reps generate intelligence that never reaches the business case, or fill the CRM with AI-gathered information that no one governs, and the case gets built from memory and guesswork. That gap is where deals die. Everything in this hub traces a familiar symptom, ghosting, discounting, a champion who cannot get internal buy-in, back to the discovery-stage failure that caused it.

Featured

Why does discovery quality decide the deal?

Weak discovery produces a business case the buyer will not carry.

The Hidden Cost of Poor Discovery
Sales teams are often more concerned about “doing discovery” than about the quality of the discovery done. Ultimately, poor discovery costs your business money. It wastes your sales team’s time and resources and makes your entire business less efficient.

Why do strong-looking deals end in no-decision?

The critical business issue was never uncovered, so nothing forces a decision.

Value is the language of consensus
Buying groups are getting larger and more complex. Even smaller $50k SaaS decisions often involve +10 stakeholders. So if you’re a B2B seller and don’t have ‘guiding buyer consensus’ at the top of mind – then you’re probably toast...
How to Make Your Revenue Growth More Predictable
CEOs and revenue leaders across enterprise SaaS all grapple with forecasting revenue numbers. Getting forecasts wrong means agitated investors and difficulty making strategic decisions. Leaders should be able to look at a pipeline and say that a deal has X chance of closing within X months...
It’s all about consensus
The attributes required for successful enterprise software sales in 2021 have changed radically. I’ve seen a seismic change in buying behavior in the last 18 months that has fundamentally changed the way we need to operate. That change is the growth in size of buying groups which are now twice or even three times the usual number…

Does methodology compliance fix no-decision?

MEDDPICC ticked in the CRM is not the same as a qualified deal.

Why don't AI research tools move pipeline?

They automate information gathering without governing it, so the case is still built on slop.

CUSTOMERS

Trusted by the best customer facing teams

Switching from another tool

“Cuvama is truly unique in focusing on collaborative discovery to drive a value-based conversation”

Francesco Colavita
Global VP PreSales, JAGGAER
Implementing & reinforcing a sales methodology

“When I saw Cuvama I realized there was actually technology that could help enable my sales team to uncover pain and demonstrate value”

Mark Gemberling
VP of Sales for RFgen

Video & Webinars

FREQUENTLY ASKED

Questions

Most stall because nobody ever built a case the buyer could defend without the seller in the room. The deal looks healthy through demo and evaluation, then it meets a finance review or a committee the seller never sees, and the argument does not hold. What failed there was not the pitch, it was the discovery months earlier that never got converted into a quantified argument. By the time the stall shows up in the forecast, the cause is already old.

Discovery is where you find the business issue, who owns it, and what it costs to leave alone. The business case is the argument for spending money to fix it. The industry treats these as two stages with a handoff in the middle, and that handoff is the problem, because whatever was learned in discovery has to be remembered, re-typed, or guessed at when the case gets built. They work when they run as one continuous motion, where the case is being assembled from validated inputs the whole way through.

Not on its own. MEDDPICC is a language for qualification, and it tells you what a seller should know about a deal. It does not tell you whether what they wrote down is true, whether the pain is worth real money, or whether the champion can defend the number in a room you are not in. A fully completed MEDDPICC record and a business case that dies at finance review coexist comfortably, which is why compliance and win rate so often move independently.

Because research is not a reason to buy. These tools automate information gathering, and gathering is not discovery, since discovery requires judgment about which problem matters to this buyer and what it is worth to them. The output lands in the CRM, nobody converts it into a quantified argument, and the seller walks in better briefed but with the same missing case. More information, same outcome.

An Upfront Value PoV is a first version of the value hypothesis, narrative and numbers together, prepared before the first meeting: the problem we believe you have, why it persists, and roughly what it is costing. It changes the deal because it gives the seller something specific to be wrong about out loud. The buyer corrects it, and that correction is the discovery. It is a starting point to be refined with your champion rather than a finished case, which is exactly why buyers engage with it.

See what an Upfront Value PoV looks like for one of your live deals. Narrative and numbers, a first version your champion can build on. No pitch.